Survival of Monocytes Collected From Patients With Atrophic AMD in Retinal Pigmented Epithelium Explants

Launched by HOSPICES CIVILS DE LYON · Jan 4, 2021

Keywords

ClinConnect Summary

This clinical trial is looking at a specific type of eye disease called age-related macular degeneration (AMD), which can lead to vision loss. The researchers want to understand how certain immune cells, called monocytes, behave in patients with a slow-progressing form of AMD known as atrophic AMD. They believe that monocytes taken from these patients may survive better when placed in a lab setting, compared to those from healthy individuals. By studying these cells, the team hopes to find specific molecules that could lead to new treatments for atrophic AMD, which currently has no effective therapy.

To be eligible for this study, participants must be over 50 years old and provide consent to take part. They should have AMD in both eyes or have one eye affected by AMD and the other eye healthy. However, people with certain other health conditions or who are on specific medications may not be able to participate. If someone joins this trial, they will provide a small sample of their blood, and the researchers will study how well the monocytes from their blood survive in a special lab environment over 24 hours. This could help pave the way for future treatments aimed at reducing the harmful effects of these cells in AMD.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• General criteria:
• • Male or female older than 50,
• • Provide written informed consent,
• • Patient affiliated to French social security,
• • Maximum sampling volume (care + research) per 30-day period to be adapted according to the weight of the patient
• Specific criteria:
• Patient presenting in both eyes:
• • Either the same type of AMD defined according to the modified international AREDS study (Ferris et al. 2013),
• • or early AMD in one eye and atrophic AMD in the other eye, the patient will therefore be defined as being atrophic
• • or early AMD in one eye and exudative AMD in the other eye, the patient will therefore be defined as exudative,
• • or no retinal pathology (control group).
• Exclusion Criteria:
• General criteria:
• • Patient whose weight is less than 50kg,
• • Adult patient under guardianship or curatorship or unable to express consent,
• • Person deprived of liberty,
• • Patient participating in an ongoing clinical trial during the inclusion visit,
• Specific criteria:
• • Patient with atrophic AMD in one eye and exudative AMD in the other eye,
• • Patient presenting with chronic retinal pathologies other than AMD, defined according to the modified international AREDS study (Ferris et al. 2013) , in the included eye,
• • Patient taking systemic drugs with an immunomodulatory action: immunosuppressants, immunomodulators, chemotherapy or corticosteroids,
• • Patient with systemic pathologies modifying their immune status,
• • Patient with a history of diabetes,
• • Patient who had dynamic phototherapy on the included eye.